Skip to main content

Table 4 Results of univariate analysis of RE, LFS and OS

From: Favorable outcome of haploidentical hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a multicenter study in Southwest China

  RE LFS OS
Variable HR(95 % CI) P HR(95 % CI) P HR(95 % CI) P
Age       
 <40 years 1(Reference)   1(Reference)   1(Reference)  
 ≥40 years 0.752(0.279–2.026) 0.573 0.932(0.454–1.913) 0.849 0.954(0.427–2.314) 0.910
HLA disparity       
 Identical HSCT 1(Reference)   1(Reference)   1(Reference)  
 Haploidentical HSCT 0.399(0.173–0.924) 0.032 0.609(0.325–1.143) 0.123 0.889(0.438–1.803) 0.744
Duration from diagnosis to SCT       
 <180 days 1(Reference)   1(Reference)   1(Reference)  
 ≥180 days 1.775(0.783–4.025) 0.169 1.389(0.740–2.609) 0.306 0.915(0.444–1.886) 0.810
Disease status before transplantation       
 CR1 1(Reference)   1(Reference)   1(Reference)  
 >CR1 3.289(1.429–7.569) 0.005 2.279(1.179–4.408) 0.014 1.711(0.804–3.642) 0.164
WBC at diagnosis       
 <30 × 109/L 1(Reference)   1(Reference)   1(Reference)  
 ≥30 × 109/L 2.272(1–5.165) 0.05 1.842(0.976–3.478) 0.06 1.590(0.778–3.249) 0.204
Acute GVHD       
 Yes 1(Reference)   1(Reference)   1(Reference)  
 No 0.562(0.235–1.366) 0.204 0.814(0.427–1.552) 0.532 1.208(0.595–2.451) 0.601
Chronic GVHD       
 Yes 1(Reference)   1(Reference)   1(Reference)  
 No 0.5(0.253–0.988) 0.046 0.570(0.241–1.346) 0.2 0.584(0.275–1.242) 0.162
CMV       
 Positive 1(Reference)   1(Reference)   1(Reference)  
 Negative 0.511(0.173–1.506) 0.223 1.087(0.55–2.148) 0.81 1.508(0.721–3.155) 1.508